» Articles » PMID: 15652830

Interleukin-1beta Tear Concentration in Glaucomatous and Ocular Hypertensive Patients Treated with Preservative-free Nonselective Beta-blockers

Overview
Journal Am J Ophthalmol
Specialty Ophthalmology
Date 2005 Jan 18
PMID 15652830
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To evaluate the ocular surface inflammatory response to the presence of preservatives in nonselective beta-blocker eyedrops.

Design: Prospective, crossover, single-masked, randomized clinical study.

Methods: study population: Twenty primary open-angle glaucoma or ocular hypertensive patients were divided in two groups, one treated with preservative-free timolol 0.5% (group 1) and the other with preserved timolol 0.5% (group 2) eyedrops. After 60 days of therapy and 3 more weeks of washout, the two groups switched to the other therapy. procedure: At each visit, basal tear samples were collected from the inferior conjunctival fornix for the determination of interleukin (IL)-1beta tear concentrations by an enzyme-linked immunosorbent assay. Intraocular pressure measurement, conjunctival hyperemia, superficial punctate keratitis, and tear film breakup time were evaluated. main outcome measure: IL-1beta concentration in tears following the use of preserved eyedrops.

Results: IL-1beta tear concentrations increased significantly in both groups, compared with baseline values, during preserved timolol therapy. There were no statistically significant changes in hyperemia and superficial punctate keratitis throughout the study in either group. A statistically significant breakup time reduction was observed in both groups after 30 days and after 60 days of preserved therapy.

Conclusion: The use of preservatives in timolol 0.5% eyedrops leads to tear film instability and ocular surface inflammatory changes documented by a reduction of breakup time and an increase of IL-1beta tear concentrations. Preservative-free beta-blockers are preferable for long-term hypotensive therapy to prevent ocular surface inflammation.

Citing Articles

Effects of Glaucoma Treatment on Ocular Surface and Tear Functions: Comparison of Trabeculectomy and Antiglaucoma Drops.

Mermer A, Dursun O, Bucak O, Sayar H, Bektas F, Eroz P Turk J Ophthalmol. 2024; 54(5):257-262.

PMID: 39463149 PMC: 11589238. DOI: 10.4274/tjo.galenos.2024.39277.


Comparative analysis of tear cytokines in patients with glaucoma, ocular hypertension, and healthy controls.

Mravec Bencurova D, Vyborny P, Dankova P Int Ophthalmol. 2023; 43(10):3559-3568.

PMID: 37318666 PMC: 10504217. DOI: 10.1007/s10792-023-02763-6.


The Effect of High Molecular Weight Hyaluronic Acid and Latanoprost Eyedrops on Tear Functions and Ocular Surface Status in C57/BL6 Mice.

Dogru M, Kojima T, Higa K, Igarashi A, Kudo H, Muller-Lierheim W J Clin Med. 2023; 12(2).

PMID: 36675473 PMC: 9861300. DOI: 10.3390/jcm12020544.


Clinical Tear Fluid Proteomics-A Novel Tool in Glaucoma Research.

Nattinen J, Aapola U, Nukareddy P, Uusitalo H Int J Mol Sci. 2022; 23(15).

PMID: 35897711 PMC: 9331117. DOI: 10.3390/ijms23158136.


An Evaluation of the Physicochemical Properties of Preservative-Free 0.005% (/) Latanoprost Ophthalmic Solutions, and the Impact on In Vitro Human Conjunctival Goblet Cell Survival.

Freiberg J, Hedengran A, Heegaard S, Petrovski G, Jacobsen J, Cvenkel B J Clin Med. 2022; 11(11).

PMID: 35683527 PMC: 9181163. DOI: 10.3390/jcm11113137.